. 2017 Aug 28;2(4):418–430. doi: 10.1016/j.jacbts.2017.06.005

Table 3.

Cellular Effects of 2-Day Gevokizumab Treatment in Wistar Rats With I/R

	Sham Treated	Ischemia/Reperfusion
	Sham Treated	Untreated	Gevokizumab Treated
Glutathione peroxidase activity, μmol/min/mg prot	219 ± 9	175 ± 21	168 ± 15
Catalase activity, μmol/min/mg prot	13.4 ± 1.1	16.39 ± 1.8	10.8 ± 1.1^†
Mitochondrial SOD activity, U SOD Mn/mg prot	7.2 ± 0.9	2.8 ± 0.7^∗	4.9 ± 0.8
Cytosolic SOD activity, U SOD CuZn/mg prot	4.5 ± 1.1	3.7 ± 0.7	4.4 ± 1.2
Total lymphocytes, nb/field	11. 7 ± 2.1	44. ± 6.9^∗	38.9 ± 8.1
Lymphocytes in infarct area, nb/field	2.9 ± 0.5	26.9 ± 4.4^∗	22.1 ± 5.1
Total leukocytes, nb/field	56.3 ± 15.5	241.2 ± 23.2^∗	115.3 ± 41.2^†
Leucocytes in infarct area, nb/field	13.5 ± 3.6	89.4 ± 12.0^∗	31.8 ± 11.9^†
Cleaved caspase-1 in infarct area, nb/field	0.00 ± 0.00	0.75 ± 0.25^∗	0.30 ± 0.10^†

Values are mean ± SD.

nb = 9 per group; SOD = superoxide dismutase.

^∗

p < 0.05 versus sham.

^†

p < 0.05 versus untreated I/R. n = 6 TO 10 per group.